Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Addressing Jyong Biotech’s commercial sequencing, CEO Kuo reaffirmed that the United States is the unequivocal first priority. Securing an FDA approval not only provides access to premium drug pricing ...

As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to ...

Toregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II ...

This week on "The Readout LOUD," longtime biotech exec Jeremy Levin talks about his new book and the industry's strategic turning point. Listen now.

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

The North Carolina Biotechnology Center highlighted the Triad as a prime spot for life sciences growth in the state and awarded local leaders at its annual Triad BioNight event.

Panda Biotech is bringing its certified U.S.-grown hemp to one of the world’s largest textile manufacturing systems. “What we have built with Panda Biotech is not simply a supply agreement, it is the ...

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.